The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

The move comes after Gilead has been struggling to extend the indications for its TROP2-targeting ADC Trodelvy (sacituzumab govitecan), which was the crown jewel in its $21 billion acquisition of ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

in combination with Gilead's Trodelvy® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Gilead's diversified growth includes significant gains in oncology and liver disease, with Trodelvy and Livdelzi showing strong sales and robust potential for growth. 2025 milestones include ...

Good afternoon, everyone, and welcome to Gilead's fourth quarter and full ... iMMagine-1 trial in the second to fourth line setting. Trodelvy, meanwhile, remains the only approved TROP2 ADC ...